• We are a biotech company in
    infectious diseases with a
    first marketed product.

  • Dedicated to innovation in
    vaccine research & development.

  • Valneva covers the full
    value chain from bench
    to market.

Welcome to Valneva

Joining forces to create a European biotech leader in vaccines


— December 18, 2014

Valneva Announces Start of Phase II Clinical Trial of its Clostridium difficile vaccine candidate
Download PR

— Stock information



—News, Dec. 10, 2014

Valneva: first Phase II data of Tuberculosis vaccine candidate formulated with IC31® adjuvant showed good safety and immunogenicity 
 All News

— Financial calendar

 All dates

November 6, 2014
Valneva reported its Q3 results - Best quarterly results since Vivalis/Intercell merger 

Download PR
Download Q3 Report
Download Analysts Presentation
View Webcast

— Upcoming conferences and fairs

December 3 - 4, 2014
VIC Congress
Brussels, Belgium

March 9 - 11, 2015
BioEurope Spring
Paris, France

June 15 - 18, 2015
Bio International Convention
Philadelphia, United States

Meet our Business Development team


European biotech company with worldwide presence.

Please update your browser...